Biomarkers for antipsychotic therapies

Handbook of Experimental Pharmacology

Volumn 212, Issue , 2012, Pages 339-360

  Pich, Emilio Merlo ^a,b   Vargas, Gabriel ^c   Domenici, Enrico ^b  

^a GLAXOSMITHKLINE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c AMGEN INC   (United States)

Author keywords

Biomarkers; Dopamine; Drug discovery; Endophenotypes; Fluids; Glycine transporter; Metabolomics; Neuroleptics; Personalized medicine; Proteomics; Psychoses; Schizophrenia; Transcriptomics; Translational medicine

Indexed keywords

BIOLOGICAL MARKER; BITOPERTIN; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; ENDOCANNABINOID; GLYCINE; GLYCINE TRANSPORTER; HALOPERIDOL; HOMOVANILLIC ACID; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PREALBUMIN; PROLACTIN; RNA; TRACER; VASCULOTROPIN; SLC6A9 PROTEIN, HUMAN;

ADD ON THERAPY; BIOASSAY; BLOOD ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; ENDOPHENOTYPE; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; HUMAN; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLOMICS; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUPPORT VECTOR MACHINE; TREATMENT OUTCOME; ANIMAL; CEREBROSPINAL FLUID; DRUG ANTAGONISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOMICS; PROTEOMICS; SCHIZOPHRENIA;

EID: 84870158594     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25761-2_13     Document Type: Review

References (72)

1. Alberati D, Borroni E, Moreau J, Hainzl D, Pinard E, Wettstein JG (2011) Partial occupancy of the glycine transporter type 1 in rat by RG1678 leads to efficacy in models relevant to schizophrenia. Schizophr Bull 37(Suppl 1):286
2. Albrethsen J (2011) The first decade of MALDI protein profiling: A lesson in translational biomarker research. J Proteomics 74:765-73
3. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD (2009) Endophenotypes in schizophrenia: A selective review. Schizophr Res 109:24-37
4. Barondes SH (1999) Molecules and mental illness. WH Freeman, Basingstoke
5. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC (2008) Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2872-81
6. Beuger M, van Kammen DP, Kelley ME, Yao J (1996) Dopamine turnover in schizophrenia before and after haloperidol withdrawal CSF, plasma, and urine Studies. Neuropsychopharmacology 15:75-86 (Pubitemid 26233393)
7. Bieck PR, Potter WZ (2005) Biomarkers in psychotropic drug development. Integration of data across multiple domains. Annu Rev Pharmacol Toxicol 45:227-46 (Pubitemid 40261804)
8. Borroni E, Wong DF, Wallace TL, Zhou Y, Kumar A, Pinard E, Alberati D (2011) Partial occupancy of the glycine transporter type 1 in monkey by RG1678 leads to efficacy in a model of prefrontal cortical function. Schizophr Bull 37(Suppl 1):296
9. Caffo NA (2008) Curidium Medica, plc. Company profile. Personalized Med 5:219-2
10. Catafau AN, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, García-Ribera C, Gomeni R, Merlo-Pich E, Barcelona Clinical Imaging in Psychiatry Group (2008) Pharmacokinetics and time course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 8:882-94
11. Catafau AM, Bullich S, Nucci G, Burgess C, Gray F, Merlo-Pich E, Barcelona Clinical Imaging in Psychiatry Group (2011) Contribution of SPECT measurements of D2 and 5HT2A occupancy to the clinical development of the antipsychotic SB-773812. J Nucl Med 52:526-34
12. Chertkow Y, Weinreb O, Youdim MB, Silver H (2007) Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 31:1356-62 (Pubitemid 47302546)
13. Chin L, Andersen JK, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297-303
14. Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32-8 (Pubitemid 38925088)
15. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. In: Geyer MA, Gross G (eds) Novel Antischizophrenia Treatments; Handbook of Experimental Pharmacology, vol. 213, Springer, Heidelberg
16. Czermak C, Lehofer M, Wagner EM, Prietl B, Gorkiewicz G, Lemonis L, Rohrhofer A, Legl T, Schauenstein K, Liebmann PM (2004a) Reduced dopamine D3 receptor expression in blood lymphocytes of smokers is negatively correlated with daily number of smoked cigarettes: a peripheral correlate of dopaminergic alterations in smokers. Nicotine Tob Res 6:49-54 (Pubitemid 38372473)
17. Czermak C, Lehofer M, Renger H, Wagner EM, Lemonis L, Rohrhofer A, Schauenstein K, Liebmann PM (2004b) Dopamine receptor D3 mRNA expression in human lymphocytes is negatively correlated with the personality trait of persistence. J Neuroimmunol 150:145-49 (Pubitemid 38481658)
18. Davila R, Zumarraga M, Basterreche N, Arrue A, Anguiano JB (2007) Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms. Psychiatry Res 151:163-68 (Pubitemid 46634643)
19. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM (2001) Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 51:119-32 (Pubitemid 32219735)
20. Domenici E, Muglia P (2007) The search for peripheral markers in psychiatry by genomic and proteomic approaches. Exp Opin Med Diagn 1:235-51
21. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5:e9166
22. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz SM (2008) Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58:1465-74 (Pubitemid 351705936)
23. Editorial (2011) Getting personal. Nature 473:25-34
24. Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET (2011) Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berl) 214:779-89
25. Frisoni GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G, Bonetti M, Soricelli A, Rasser PE, Thompson PM, Giannakopoulos P (2011) Alzheimer's CSF markers in older schizophrenia patients. Int J Geriatr Psychiatry 26:640-8
26. Fung ET (2010) A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56:327-9
27. German JB, Hammock BD, Watkins SM (2005) Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1:3-9
28. Gerretsen P, Müller DJ, Tiwari A, Mamo D, Pollock BG (2009) The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci 11:363-76
29. Gladkevich A, Kauffman HF, Korf J (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28:559-76 (Pubitemid 38490769)
30. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM (2011) Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 72:1616-27
31. Goodazi A, Vousooghi N, Sedaghati M, Mokri A, Zarrindast MR (2009) Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. Eur J Pharmacol 615:218-22
32. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL (2011) Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the consortium on the genetics of schizophrenia. Am J Psychiatry 168(9):930-46
33. Harvey PD (2006) Current Status of the MATRICS/TURNS Initiative. Psychiatry (Edgmont) 3:24-33
34. Hofmann C, Alberati D, Banken L, Boetsch C, Ereshefsky L, Jhee S, Moran S, Martin-Facklam M, Backholer Z, Boutouyrie-Dumont B (2011) Glycine transporter type 1 (GlyT1) inhibitor RG1678: proof of mechanism of action in healthy volunteers. Schizopr Bull 37(Suppl 1):306
35. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Reed B, Bahn S (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3:428-3
36. Huijbers A, Velstra B, Dekker TJ, Mesker WE, van der Burgt YE, Mertens BJ, Deelder AM, Tollenaar RA (2010) Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci 11:4175-93
37. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12:934-45 (Pubitemid 47482696)
38. Kalos M (2010) An integrative paradigm to impart quality to correlative science. J Transl Med 8:26
39. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first episode schizophrenia. Am J Psychiatry 157:514-20 (Pubitemid 30191189)
40. Kurian SM, Le-Niculescu H, Patel SD, Bertram D, Davis J, Dike C, Yehyawi N, Lysaker P, Dustin J, Caligiuri M, Lohr J, Lahiri DK, Nurnberger JI Jr, Faraone SV, Geyer MA, Tsuang MT, Schork NJ, Salomon DR, Niculescu AB (2011) Identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry 16:37-58
41. Kuzman MR, Medved V, Terzic J, Krainc D (2009) Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. J Psychiatric Res 43:1073-77
42. Kwak YT, Koo MS, Choi CH, Sunwoo I (2001) Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med Genet 2:3
43. Ilani T, Ben Shachar D, Strous RD, Mazor M, Sheinkman A, Kotler M, Fuchs S (2001) A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A 98:625-628 (Pubitemid 32105093)
44. Javitt DC (2010) Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 47:4-16
45. Javitt DC (2012) Glycine transport inhibitors in the treatment of schizophrenia. In: Geyer MA, Gross G (eds) Novel Antischizophrenia Treatments; Handbook of Experimental Pharmacology, vol. 213, Springer, Heidelberg
46. Lauder Lindsay W (1855) The histology of the blood in the insane. J Physiol Med Mental Pathol 1:78-93
47. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, Tsuang MT, Salomon DR, Nurnberger JI Jr, Niculescu AB (2009) Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14:156-74
48. Leweke FM, Kranaster L, Pahlisch F, Klosterkötter J, Hellmich M, Piomelli D, Koethe D (2011) The efficacy of cannabidiol in the treatment of schizophrenia - a translational approach. Schizophr Bull 37(Suppl 1):313
49. MacPhail SR (1892) Blood of the insane. In: Tuke DH (ed) A dictionary of psychological medicine (volume I). P. Blakiston and Son, Philadelphia
50. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-46 (Pubitemid 28100274)
51. Marincola FM (2003) Translational medicine: a two-way road. J Transl Med 1:1-3
52. Mikkelsen JD, Thomsen MS, Hansen HH, Lichota J (2010) Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discov Today 15:137-41
53. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1-93 (Pubitemid 40677047)
54. Noll R (2006) The blood of the insane. Hist Psychiatry 17:395-418 (Pubitemid 44704264)
55. Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17(2):97-103
56. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, Salter MW (2003) Glycine binding primes NMDA receptor internalization. Nature 422(6929):302-7 (Pubitemid 36378356)
57. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-75 (Pubitemid 29260341)
58. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13:1359-62 (Pubitemid 350073592)
59. Shariati GH, Ahangari G, Asadi MR, Poyafard F, Ahmadkhaniha HR (2009) Dopamine receptor gene expression changes in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and olanzapine. Eur J Inflammation 7:71-6
60. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38 (Pubitemid 34302921)
61. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, van Beveren NJ, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 12:39-47
62. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S (2011) Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17(5):494-502
63. Takahashi M, Hayashi H, Watanabe Y, Sawamura K, Fukui N, Watanabe J, Kitajima T, Yamanouchi Y, Iwata N, Mizukami K, Hori T, Shimoda K, Ujike H, Ozaki N, Iijima K, Takemura K, Aoshima H, Someya T (2010) Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr Res 119:210-8
64. Tavares H, Yacubian L, Talib LL, Barbosa NR, Gattaz WF (2003) Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res 61:1-6 (Pubitemid 36335816)
65. Thomasson-Perret N, Pénélaud PF, Théron D, Gouttefangeas S, Mocaër E (2008) Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin. Therapie 63:237-42
66. Tsang TM, Huang JT, Holmes E, Bahn S (2006) Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 5:756-60
67. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, Shyu KG, Glatt SJ, Liew CC (2005) Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133:1-5 (Pubitemid 40175606)
68. 2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31(3):318-25
69. Umbricht D, Martin-Facklam M, Pizzagalli F, Youssef E, Yoo K, Dorflinger E, Bausch A, Arrowsmith R, Alberati D, Santarelli L (2011) Glycine transporter type 1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophr Bull 37(Suppl 1):324
70. USA Food and Drug Administration (2004) Challenges and Opportunities Report - March 2004. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262. htm
71. Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C (2010) Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 12:R211
72. Vogel M, Pfeifer S, Schaub RT, Grabe HJ, Barnow S, Freyberger HJ, Cascorbi I (2004) Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50:305-10 (Pubitemid 39482670)